Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $72.67 -0.48%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- CalPrivate Bank names Andra Frazier as chief credit officer
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
